Squarepoint
APLS

Squarepoint’s Apellis Pharmaceuticals APLS Stock Holding History

Squarepoint’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,000
Closed -$898K – 3980
2023
Q4 		$898K Buy
+15,000
New +$761K ﹤0.01% 2599

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Squarepoint's APLS Position: Q1 2026 in Review

Squarepoint increased its Apellis Pharmaceuticals (APLS) stake by 134% in Q1 2026, buying an estimated $5.55M and bringing the position to 449,796 shares worth $18.1M. The position accounts for 0.02% of the portfolio, ranked #761.

Squarepoint first reported a position in APLS in Q3 2018 and has held it in 21 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Squarepoint held 449,796 shares of Apellis Pharmaceuticals worth $18.1M as of Q1 2026.
  • Squarepoint bought 257,640 Apellis Pharmaceuticals shares in Q1 2026, an estimated $5.55M.
  • Apellis Pharmaceuticals made up 0.02% of Squarepoint's portfolio in Q1 2026, its #761 holding.
  • Squarepoint first reported a position in Apellis Pharmaceuticals in Q3 2018 and has held it in 21 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.